ArticleFrontiers in immunology2024
Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
8.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis.Rheumatology (Oxford, England) · 2026Pooled it
- Influencing factors for rapidly progressive interstitial lung disease in patients with anti-MDA5 antibody-positive dermatomyositis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Determinants for worsening in systemic autoimmune rheumatic disease-associated interstitial lung disease: a systematic review and meta-analysis of cohort studies.Frontiers in medicine · 2024Pooled it
- Observational
- Preliminary nomogram model for predicting respiratory failure of patients with idiopathic inflammatory myopathies.Scientific reports · 2026Article
- Monocytoid dendritic cells might be a specific marker for lung involvement in dermatomyositis.Diagnostic pathology · 2026Article
- Clinical characteristics and long-term prognosis of anti-MDA5-positive dermatomyositis: a comparative study across age groups.Orphanet journal of rare diseases · 2026Article
- The clinical values of laboratory inflammatory and composite indices in predicting rapidly progressive interstitial lung disease and prognosis in anti-MDA5 dermatomyositis patients.Clinical rheumatology · 2026Article
- Machine learning for predicting acute exacerbation and mortality in idiopathic inflammatory myopathy-associated interstitial lung disease.Frontiers in medicine · 2026Article
- Increased severity and relapse rate in adult anti-nuclear matrix protein 2 antibody positive myositis patients with distal limb weakness: a retrospective study in China.Frontiers in medicine · 2026Article
- Semiquantitative HRCT scoring: a reliable predictor of rapidly progressive interstitial lung disease in patients with anti-MDA5 positive dermatomyositis.Quantitative imaging in medicine and surgery · 2026Article
- Prognostic value of HRCT-based risk stratification for acute/subacute progression in polymyositis/dermatomyositis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Spontaneous pneumomediastinum and/or pneumothorax in anti-MDA5 dermatomyositis: a refined staging system.Respiratory research · 2025Article
- Article
- Rare but not to be overlooked: Epidemiology and strategies for rare dermatological diseases in China.Intractable & rare diseases research · 2025Review
- Clinical characteristics and outcomes of anti-MDA5 dermatomyositis: a retrospective study.BMC rheumatology · 2025Article
- Identifying two pathways to poor prognosis in patients with anti-MDA5 antibodies: insights from prognostic factor and cytokines analysis.Arthritis research & therapy · 2025Article
- Clinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies.Clinical rheumatology · 2025Article
- Case Report: Spontaneous pneumomediastinum in a patient with MDA5-positive dermatomyositis and severe pulmonary fibrosis.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 15 institutions in 1 country.
Lei WangDivision of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Chengyin LvDivision of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Hanxiao YouDivision of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Lingxiao XuDivision of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Fenghong YuanDivision of Rheumatology, Wuxi People's Hospital, Wuxi, Jiangsu, China.
Ju LiDivision of Rheumatology, Huai'an First People's Hospital, Huai'an, Jiangsu, China.
Min WuDivision of Rheumatology, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Shiliang ZhouDivision of Rheumatology, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Zhanyun DaDivision of Rheumatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Jie QianDivision of Rheumatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Hua WeiDivision of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.
Wei YanDivision of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.
Lei ZhouDivision of Rheumatology, Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China.
Yan WangDivision of Rheumatology, Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China.
Songlou YinDivision of Rheumatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Dongmei ZhouDivision of Rheumatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Jian WuDivision of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Yan LuDivision of Rheumatology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, China.
Dinglei SuDivision of Rheumatology, Nanjing First Hospital, Nanjing, Jiangsu, China.
Zhichun LiuDivision of Rheumatology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Lin LiuDivision of Rheumatology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Longxin MaDivision of Rheumatology, Yancheng No.1 People's Hospital, Yancheng, Jiangsu, China.
Xiaoyan XuDivision of Rheumatology, Zhongda Hospital Southeast University, Nanjing, Jiangsu, China.
Yinshan ZangDivision of Rheumatology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China.
Huijie LiuDivision of Rheumatology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Tianli RenDivision of Rheumatology, Wuxi No.2 People's Hospital, Wuxi, Jiangsu, China.
Jin LiuResearch Institute of Clinical Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Fang WangDivision of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Miaojia ZhangDivision of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Wenfeng TanDivision of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Jiangsu Province Hospital · CNNanjing Medical University · CNChangzhou No.2 People's Hospital · CNNantong University · CNNorthern Jiangsu People's Hospital · CNThe First People's Hospital of Changzhou · CNXuzhou Medical College · CNFirst Affiliated Hospital of Soochow University · CNHuaian First People’s Hospital · CNSoochow University · CNThe First People’s Hospital of Lianyungang · CNWuxi No.2 People's Hospital · CNWuxi People's Hospital · CNXuzhou Central Hospital · CNZhongda Hospital Southeast University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of anti-melanoma differentiation-associated gene 5 positive dermatomyositis (anti-MDA5 Methods: Patients with anti-MDA5 Results: There are no significant differences in baseline clinical parameters and prognosis between discovery and validation cohorts. Among all 255 anti-MDA5 Conclusions: The CROSS model is an easy-to-use prediction classification system for RP-ILD risk in anti-MDA5
Indexed as
DermatomyositisLung Diseases, InterstitialAutoantibodiesHumansInterferon-Induced Helicase, IFIH1MaleRetrospective StudiesAutoantibodiesInterferon-Induced Helicase, IFIH1anti-melanoma differentiation-associated gene 5dermatomyositiseasy-to-usepredict modelsrapidly progressive interstitial lung disease
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.